COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,442 Articles (22,835 medRxiv, 8,607 bioRxiv)

Most recent first Previous |  Page 1064: Articles 10631-10640  | Next

Accelerating manufacturing to start large-scale supply of a new adenovirus-vectored vaccine within 100 days
Joe, C. C., Segireddy, R. R., Oliveira, C., Berg, A., Li, Y., Doultsinos, D., Chopra, N., Scholze, S., Ahmad, A., Nestola, P., Niemann, J., Douglas, A.
10.1101/2021.12.22.473478 — Posted: 2021-12-23
Surveillance and correlation of SARS-CoV-2 viral RNA, antigen, virus isolation, and self-reported symptoms in a longitudinal study with daily sampling
Bonenfant, G., Deyoe, J., Wong, T., Grijalva, C. G., Talbot, H. K., Halasa, N., Chappell, J., Cui, D., Hassell, N., Thornburg, N. J., Rolfes, M. A., Wentworth, D., Zhou, B.
10.1101/2021.12.23.21268319 — Posted: 2021-12-23
Dynamics of immune recall following SARS-CoV-2 vaccination or breakthrough infection
Koutsakos, M., Lee, W. S., Reynaldi, A., Tan, H.-X., Gare, G., Kinsella, P., Liew, K. C., Williamson, D. A., Kent, H. E., Stadler, E., Cromer, D., Khoury, D. S., Wheatley, A. K., Juno, J. A., Davenport, M. P., Kent, S. J.
10.1101/2021.12.23.21268285 — Posted: 2021-12-23
Seroconversion rate after primary vaccination with two doses of BNT162b2 versus mRNA-1273 in solid organ transplant recipients: a systematic review and meta-analysis
Verleye, A., Wijtvliet, V., Abrams, S., Hellemans, R., Bougrea, R., Massart, A., Pipeleers, L., Wissing, K. M., De Winter, B. Y., Van Damme, P., Abramowicz, D., Ledeganck, K. J.
10.1101/2021.12.23.21268314 — Posted: 2021-12-23
A systematic review of observational methods used to quantify personal protective behaviours among members of the public during the COVID-19 pandemic, and the concordance between observational and self-report measures in infectious disease health protection
Davies, R., Mowbray, F., Martin, A. F., Smith, L. E., Rubin, G. J.
10.1101/2021.12.22.21268226 — Posted: 2021-12-23
Persistent symptoms among children and adolescents with and without anti-SARS-CoV-2 antibodies: a population-based serological study in Geneva, Switzerland
Dumont, R., Nehme, M., Lorthe, E., De Mestral, C., Richard, V., Lamour, J., Baysson, H., Semaani, C., Pennacchio, F., Perrin, A., L'Huillier, A. H., Posfay Barbe, K., Pullen, N., Zaballa, M. E., Guessous, I., Stringhini, S.
10.1101/2021.12.23.21268298 — Posted: 2021-12-23
A magnetic bead immunoassay to detect human IgG reactive to SARS-CoV-2 Spike S1 RBD produced in Escherichia coli
Conzentino, M. d. S., Goncalves, A. C., Paula, N. M., Rego, F. G., Zanette, D., Aoki, M., Nardin, J. M., Huergo, L. F.
10.1101/2021.12.22.21268286 — Posted: 2021-12-23
Efficacy of antiviral drugs against the omicron variant of SARS-CoV-2.
Dabrowska, A., Szczepanski, A., Botwina, P., Mazur-Panasiuk, N., Jirincova, H., Rabalski, L., Zajic, T., Popowicz, G., Pyrc, K.
10.1101/2021.12.21.473268 — Posted: 2021-12-23
Nucleocapsid 203 mutations enhance SARS-CoV-2 immune evasion
Lin, X., Xue, W., Zhang, Y., Fu, B., Trimpert, J., Xing, N., Kunec, D., Tang, W., Xiao, Y., Meng, K., Shi, S., Wu, H., Meng, G., Zhu, Z.
10.1101/2021.12.20.473471 — Posted: 2021-12-23
Construction of a potent pan-vaccine based on the evolutionary tendency of SARS-CoV-2 spike protein.
Zhao, Y., Ni, W., Liang, S., Dong, L., Xiang, M., Cai, Z., Niu, D., Zhang, Q., Wang, D., Zheng, Y., Zhang, Z., Zhou, D., Guo, W., Pan, Y., Wu, X., Yang, Y., Jing, Z., Jiang, Y., SARS-CoV-2 Vaccine Task Force Group, , Chen, Y., Yan, H., Zhou, Y., Xu, K., Lan, K.
10.1101/2021.12.21.473594 — Posted: 2021-12-23

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).